Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma is a research paper published in Cancer Discovery (2021). On theSindex it has a DataRank of 0.700. It has been cited 105 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.700
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH NCI NCTN
Grant: CA180888
NIH NCI NCTN
Grant: CA180819
NIH NCI NCTN
Grant: CA180820
NIH NCI NCTN
Grant: CA180863
NIH NCI NCTN
Grant: UG1CA233178
NIH NCI NCTN
Grant: UG1CA233329
NIH NCI NCTN
Grant: UG1CA189821
NIH NCI NCTN
Grant: UG1CA233331
NIH NCI NCTN
Grant: UG1CA233324
NIH NCI
Grant: R35 CA197633
NIH NCI
Grant: P01 CA244118
National Institutes of Health
Grant: 5UG1CA189821-04
Kaiser Permanente NCI National Community Oncology Research Program NCORP
National Institutes of Health
Grant: 2R35CA197633-08
Next Generation Cancer Immunotherapies to Defeat Melanoma
National Institutes of Health
Grant: 5UG1CA233178-04
Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application
National Institutes of Health
Grant: 5U10CA180863-08
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network
National Institutes of Health
Grant: 5UG1CA233329-06
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1
National Institutes of Health
Grant: 2U10CA180819-06
SWOG Statistics and Data Management Center
National Institutes of Health
Grant: 5UG1CA233324-03
NCI National Clinical Trials Network - Lead Academic Participant Sites
National Institutes of Health
Grant: 5UG1CA233331-03
OSU as a Network Lead Academic Participating Site for the NCI NCTN
National Institutes of Health
Grant: 1P01CA244118-01A1
Combination Therapies to Defeat Melanoma Resistance
National Institutes of Health
Grant: 3U10CA180888-03S1
SWOG Network Group Operations Center of the NCTN
National Institutes of Health
Grant: 3U10CA180820-02S3
ECOG-ACRIN Operations Center
Fields of Study
Keywords
Sustainable Development Goals